article thumbnail

Evolving Capacity to Meet Advanced Biologics Therapies

MedCity News

Creating adequate capacity for any therapeutic can be challenging, and the specialized technologies for manufacturing complex biologics require flexibility and agility in production processes. The post Evolving Capacity to Meet Advanced Biologics Therapies appeared first on MedCity News.

article thumbnail

Medical Devices Are Evolving Toward Specialized Solutions

MedCity News

As medical devices evolve and become more sophisticated, we are seeing a trend toward specialization. Building customized solutions for specialized disease states creates a nimbleness to respond to new conditions and develop a platform uniquely suited for that condition. It will become commonplace to see devices that break new ground.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fast-growing Adragos snaps up Swiss CDMO Baccinex, significantly expanding fill-finish firepower

Fierce Pharma

Now, the manufacturing arriviste—which was founded in 2020—is expanding its production network again with the acquisition of Switzerland's Baccinex, which specializes in fill and finish services.

article thumbnail

Ajinomoto Adds Gene Therapy to CDMO Scope via $554M Forge Bio Buyout

MedCity News

Ajinomoto’s Forge Biologics acquisition brings contract development and manufacturing organization capabilities in gene therapy. Forge specializes in manufacturing AAV vectors used to deliver these therapies.

article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements. It is crucial to ensure supply chain risks are mitigated and have proactive strategies in place to address unforeseen challenges before they become an issue.

article thumbnail

High-flying Fujifilm splashes $200M to beef up cell therapy capacity

Fierce Pharma

Fujifilm Corporation is spreading the wealth across two production units as the contract development and manufacturing organization (CDMO) juggernaut works through a cell therapy expansion. Fujifilm is dividing $200 million between a pair of subsidiaries.

article thumbnail

Novo Nordisk plans new $220M raw ingredients plant in Denmark

Fierce Pharma

Even as supplies of Novo Nordisk’s immensely popular GLP-1 drugs Ozempic and Wegovy start to stabilize, the Danish drugmaker continues to announce manufacturing and capacity upgrades at a rapid cli | Novo Nordisk Pharmatech, a unit that specializes in producing drug ingredients, is spending 1.5

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial.